Cannabinoid receptor compounds enhanced the antidepressant effects of atypical medications in mice
In mice, both CB1 agonists and antagonists enhanced antidepressant effects of tianeptine, while CB1 and CB2 antagonists augmented agomelatine, all without changing brain drug levels.
Quick Facts
What This Study Found
In mouse forced swim and tail suspension tests, sub-effective doses of CB receptor ligands enhanced antidepressant activity: oleamide (CB1 agonist) potentiated tianeptine; AM251 (CB1 antagonist) enhanced both tianeptine and agomelatine; AM630 (CB2 inverse agonist) augmented both drugs in the forced swim test only. None of the combinations affected brain levels of the antidepressants, indicating pharmacodynamic rather than pharmacokinetic interaction.
Key Numbers
Oleamide 5 mg/kg + tianeptine 15 mg/kg: significant anti-immobility in FST and TST; AM251 0.25 mg/kg enhanced both drugs; AM630 0.25 mg/kg enhanced both in FST only; no brain level changes.
How They Did This
Mouse behavioral studies using forced swim test (FST) and tail suspension test (TST) to assess antidepressant-like effects of cannabinoid receptor ligands combined with atypical antidepressants (agomelatine, tianeptine). HPLC measured brain drug levels.
Why This Research Matters
Atypical antidepressants like agomelatine and tianeptine work through unique mechanisms (melatonin and opioid pathways). Finding that cannabinoid compounds enhance their effects without changing brain concentrations suggests a true synergistic interaction worth exploring.
The Bigger Picture
That both CB1 activation (oleamide) and CB1 blockade (AM251) enhanced antidepressant effects seems contradictory but may reflect dose-dependent or receptor-population-specific effects. This complexity suggests the endocannabinoid system modulates mood through multiple pathways.
What This Study Doesn't Tell Us
Animal model only (mouse behavioral tests have limited translational value); sub-effective doses may not translate to clinical use; forced swim test validity debated; only two atypical antidepressants tested; acute dosing only.
Questions This Raises
- ?How can both CB1 activation and blockade enhance antidepressant effects?
- ?Would cannabinoid augmentation reduce the effective dose of antidepressants needed in humans?
Trust & Context
- Key Stat:
- Both CB1 activation and blockade enhanced atypical antidepressant effects in mice
- Evidence Grade:
- Preliminary: animal behavioral study with limited translational certainty.
- Study Age:
- Published 2020.
- Original Title:
- Influence of the CB1 and CB2 cannabinoid receptor ligands on the activity of atypical antidepressant drugs in the behavioural tests in mice.
- Published In:
- Pharmacology, biochemistry, and behavior, 188, 172833 (2020)
- Authors:
- Poleszak, Ewa(2), Wośko, Sylwia(2), Sławińska, Karolina(2), Wyska, Elżbieta, Szopa, Aleksandra, Świąder, Katarzyna, Wróbel, Andrzej, Doboszewska, Urszula, Wlaź, Piotr, Wlaź, Aleksandra, Serefko, Anna
- Database ID:
- RTHC-02785
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Can cannabinoids improve antidepressant effectiveness?
In mice, cannabinoid receptor compounds enhanced the antidepressant effects of tianeptine and agomelatine at doses too low to work alone. The interaction was pharmacodynamic (brain drug levels unchanged), suggesting true synergy.
Would this work in humans?
Unknown. Mouse behavioral tests are a starting point but have limited translational value. Human trials would need to address dosing, safety, and the complexity of cannabinoid receptor effects across different brain regions.
Read More on RethinkTHC
- LGBTQ-cannabis-use-recovery-support
- cannabis-induced-psychosis
- online-therapy-cannabis-anxiety-review
- quitting-weed-adhd
- quitting-weed-depression
- quitting-weed-ptsd
- self-medicating-with-weed
- weed-OCD-intrusive-thoughts
- weed-and-ptsd
- weed-childhood-trauma-ACE
- weed-suicidal-thoughts-withdrawal
- thc-and-ssris-cannabis-antidepressants
Cite This Study
https://rethinkthc.com/research/RTHC-02785APA
Poleszak, Ewa; Wośko, Sylwia; Sławińska, Karolina; Wyska, Elżbieta; Szopa, Aleksandra; Świąder, Katarzyna; Wróbel, Andrzej; Doboszewska, Urszula; Wlaź, Piotr; Wlaź, Aleksandra; Serefko, Anna. (2020). Influence of the CB1 and CB2 cannabinoid receptor ligands on the activity of atypical antidepressant drugs in the behavioural tests in mice.. Pharmacology, biochemistry, and behavior, 188, 172833. https://doi.org/10.1016/j.pbb.2019.172833
MLA
Poleszak, Ewa, et al. "Influence of the CB1 and CB2 cannabinoid receptor ligands on the activity of atypical antidepressant drugs in the behavioural tests in mice.." Pharmacology, 2020. https://doi.org/10.1016/j.pbb.2019.172833
RethinkTHC
RethinkTHC Research Database. "Influence of the CB1 and CB2 cannabinoid receptor ligands on..." RTHC-02785. Retrieved from https://rethinkthc.com/research/poleszak-2020-influence-of-the-cb1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.